Abstract
Background
Patients with pancreatic tumors that induce hypoglycemia present with a myriad of symptoms. Laboratory testing can frequently result in data challenging to the clinician to confirm the biochemical diagnosis. Proinsulin, in addition to insulin levels, may be essential in evaluating and diagnosing an insulinoma.
Methods
The objective of this case report is to demonstrate the potential importance of proinsulin levels in the evaluation of tumor-induced hypoglycemia. We report a 49-year-old woman with an unusual clinical presentation. Unlike many patients with tumor-induced hypoglycemia, her fasting glucose levels were fairly unimpressive, her insulin levels were undetectable during a prolonged fast, and she had elevated proinsulin levels.
Results
The inpatient fast was remarkable for levels of serum glucose 53 mg/dl or higher, a serum insulin <2 uIU/ml, C-peptide 0.7–1.1 (nl 0.8–3.1 ng/ml), and proinsulin 29.2–36.8 pmol/l (nl ≤ 18.8 pmol/l). CT scanning of the abdomen revealed multiple pancreatic lesions. A laparoscopic distal pancreatectomy led to the removal of multiple neuroendocrine tumors, which stained only for proinsulin and not for other pancreatic tumor markers. Postoperatively, she normalized her biochemical serum studies and has remained symptom-free 2 years later.
Conclusions
The measurement of proinsulin plays an important part in the diagnostic workup of neuroendocrine tumors causing hypoglycemia. These potentially malignant tumors can be treated adequately with minimally invasive surgery.
Similar content being viewed by others
References
Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P (2000) Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 85:3222–3226
Service FJ (1995) Hypoglycemic disorders. N Engl J Med 332:1144–1152
O’Brien T, O’Brien PC, Service FJ (1993) Insulin surrogates in insulinoma. J Clin Endocrinol Metab 77:448–451
Hale PJ, Nattrass M (1989) Metabolic profiles in patients with insulinomas. Clin Endocrinol (Oxf) 30:29–38
McMahon MM, O’Brien PC, Service FJ (1989) Diagnostic interpretation of the intravenous tolbutamide test for insulinoma. Mayo Clin Proc 64:1481–1488
Finlayson E, Clark OH (2004) Surgical treatment of insulinomas. Surg Clin North Am 84:775–785
Piovesan A, Pia A, Visconti G, Terzolo M, Leone A, Magro G, Cesario F, Borretta G (2003) Proinsulin-secreting neuroendocrine tumor of the pancreas. J Endocrinol Invest 26:758–761
Roth J, Komminoth P, Heitze PU (1995) Topographic abnormalities of proinsulin to insulin conversion in functioning human insulinomas. Am J Pathol 147:489–502
Wiesli P, Perren A, Saremaslani P, Pfammatter T, Spinas GA, Schmid C (2004) Abnormalities of proinsulin processing in functioning insulinomas: clinical implications. Clin Endocrinol 61:424–430
Ipp E, Griffiths SM, Bowsher RR, Tarris RH, Zhou DB, Terlecki ME (1992) Fluctuations in plasma proinsulin in an insulinoma. Diabetes Care 15:931–933
Gorden P, Skarulis MC, Roach P, Comi RJ, Fraker DL, Norton JA, Alexander HR, Doppman JL (1995) Plasma proinsulin-like component in insulinoma: a 25-year experience. J Clin Endocrinol Metab 80:2884–2887
Tasaka Y, Nakaya F, Matsumoto H, Odagiri R, Ohgawara H, Omori Y (1993) Tumor and serum levels of proinsulin and insulin in insulinoma patients. Endocr J 40:245–248
Chia CW, Saudek CD (2003) The diagnosis of fasting hypoglycemia due to an islet cell tumor obscured by a highly specific insulin assay. J Clin Endocrinol Metab 88:1464–1467
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, G., Sadur, C. & Puligandla, B. Multiple Proinsulin-Secreting Tumors of the Pancreas Treated by Laparoscopic Distal Pancreatectomy and Splenectomy. World J Surg 33, 397–399 (2009). https://doi.org/10.1007/s00268-008-9772-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-008-9772-9